Table 1.
The Correlation Between miR-934 Expression and Clinicopathological Features of Patients with Pancreatic Cancer
| Characteristics | n=139 | miR-934 | P value | ||
|---|---|---|---|---|---|
| Low Expression | High Expression | ||||
| Age | <60 years | 41 (29.5%) | 19 (46.3%) | 22 (53.7%) | 0.615 |
| ≥60 years | 98 (70.5%) | 50 (51.0%) | 48 (49.0%) | ||
| Gender | Male | 63 (45.3%) | 32 (50.8%) | 31 (49.2%) | 0.804 |
| Female | 76 (54.7%) | 37 (48.7%) | 39 (51.3%) | ||
| Pathologic Stage | I+II | 131 (94.2%) | 68 (51.9%) | 63 (48.1%) | 0.030 |
| III+IV | 8 (5.8%) | 1 (12.5%) | 7 (87.5%) | ||
| T Stage | T1+T2 | 21 (15.1%) | 11 (52.4%) | 10 (47.6%) | 0.785 |
| T3+T4 | 118 (84.9%) | 58 (49.2%) | 60 (50.8%) | ||
| N Stage | N0 | 37 (26.6%) | 17 (45.9%) | 20 (54.1%) | 0.814 |
| N1 | 59 (42.4%) | 31 (52.5%) | 28 (47.5%) | ||
| N2 | 43 (31.0%) | 21 (48.8%) | 22 (51.2%) | ||
| M Stage | M0 | 66 (47.5%) | 31 (47.0%) | 35 (53.0%) | 0.277 |
| M1 | 5 (3.6%) | 1 (20.0%) | 4 (80.0%) | ||
| Mx | 68 (48.9%) | 37 (54.4%) | 31 (45.6%) | ||
| R Stage | R0 | 83 (59.6%) | 44 (53.0%) | 39 (47.0%) | 0.641 |
| R1 | 50 (36.0%) | 22 (44.0%) | 28 (56.0%) | ||
| R2 | 3 (2.2%) | 2 (66.7%) | 1 (33.3%) | ||
| Rx | 3 (2.2%) | 1 (33.3%) | 2 (66.7%) | ||